vaniprevir

InvivoChem Cat #:V4366CAS #:923590-37-8Purity >=98%

Description: Vaniprevir (formerly known as MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is is a macrocyclic that is being developed by Merck & Co., and is currently in clinical testing. In Japan, it was approved in Japan for treating hepatitis C in 2014 under the brand name Vanihep. Vaniprevir is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species. Vaniprevir is a potent HCV protease inhibitor with a predictable resistance profile and favorable safety profile that is suitable for QD or BID administration.

References: J Med Chem. 2010 Mar 25; 53(6):2443-63.

-20C for 3 years in powder form

Synonym: MK7009; MK-7009; MK 7009
IUPAC/Chemical Name: Cyclopropanecarboxamide, N-(((6-(2-carboxy-2, 3-dihydro-1H-isoindol-4-yl)-2, 2-dimethylhexyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1-2)-lactone, (1R, 2R)-
InChi Key: KUQWGLQLLVFLSM-ONAXAZCASA-N
InChi Code: InChI=1S/C38H55N5O9S/c1-7-25-18-38(25, 33(46)41-53(49, 50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2, 3)4)39-34(47)51-22-37(5, 6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10, 12-13, 25-27, 29-30H, 7-9, 11, 14-22H2, 1-6H3, (H, 39, 47)(H, 40, 44)(H, 41, 46)/t25-, 26-, 29+, 30-, 38-/m1/s1
SMILES Code: CC[CH]1C[C]1(C(NS(=O)(C2CC2)=O)=O)NC([CH]3C[CH]4CN3C([CH](C(C)(C)C)NC(OCC(C)(CCCCC5=CC=CC6=C5CN(C(O4)=O)C6)C)=O)=O)=O